- COVID Vaccines for All American Adults by the End of May: Biden
- Health Highlights: March 3, 2021
- Talking Points: People Rarely End Conversations When They Want To
- ‘Rerouting’ Brain Blood Flow: Old Technique Could Be New Advance Against Strokes
- NIH Halts Trial of Convalescent Plasma for Mild COVID-19
- Choice of Brand-Name Drug Over Generics Costs Medicare Nearly $2 Billion Annually
- Does an Arthritis Drug Help Patients Battling Severe COVID? It Depends on the Study
- Patients With Sickle Cell Disease Often Overlooked for Life-Saving Kidney Transplants
- Scientists Gain Insight Into Genetics of Glaucoma
- Social Media, Binge Eating Often Go Together for Kids
Heartburn Drug Kapidex Renamed to Dexilant
THURSDAY, March 4Kapidex (dexlansoprazole) has been given the new name Dexilant — so approved by the U.S. Food and Drug Administration — to avoid confusion with other drugs that have similar names.
There is no problem with Kapidex itself and, other than the name switch, nothing else will be changed about the drug, the FDA said. It’s a proton pump inhibitor, used to treat heartburn and other conditions caused by excess stomach acid.
In a news release, the FDA cited pharmacy errors in dispensing Kapidex, approved in January 2009, citing confusion with the drugs Casodex and Kadian. All three drugs have widely different uses; Casodex is prescribed for prostate cancer and Kadian to treat pain.
The newly named heartburn drug will begin appearing on store shelves in late April, the FDA said. It’s manufactured by Takeda Pharmaceuticals North America.
More information
The FDA has more about this drug’s approval history.
Source: HealthDay
